Overview

We source and offer patients' access to some of the worlds best biomarker chem path tests in order to detect pathology early, allow clinicians to classify risk in their patients, set a multitude of lifestyle treatment goals and focus on patients longevity. Lipoprotein Associated Phospholipase A2 (Lp-PLA2 or i-plaq) testing for Southern Africa will be available early in 2024. We currently validating testing now through one of the largest RSA path laboratory chain's and this specific cardiac panel testing will be made available to clinicians later this year across SA. It's approved by the largest medical aids in South Africa and will be coded into the new SAMA 2014 book edition. >50% of all cardiac events strike in individuals with unremarkable lipid levels and LDL-C Level Alone is NOT a Reliable Predictor for CVD. NO blood test has existed to aid in assessing stroke risk – until the Lp-PLA2 Test. Tracking the "reduction" in Lp-PLA2 and LDL-C together in response to therapy is a better indicator of future CVD events than the reduction of LDL-C alone. People with high Lp-PLA2 levels have increased risk of CVD events independent from other CVD risk factors. We offer Medical Insurers costs savings though early detection in order to help mitigate morbidity and expensive events i.e. heart attacks, stokes and rehabilitation. We currently offering people access to a very specific heart disease test called "i-plaq" which is effective in identifying high risk cardiac disease patients with inflamed atherosclerotic plaque lesions which may be more than 2-fold more likely to have heart attacks and stokes.